Article - 13/11/2017 An artificial heart valve with the potential to grow About 30,000 artificial heart valves are implanted in Germany every year. The durability of these heart valves presents a major challenge, requiring them to be exchanged time and again, especially in young patients. Researchers from the Stuttgart Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB have developed a new artificial heart valve material on which cells that are naturally present in a patient’s blood can form new…https://www.gesundheitsindustrie-bw.de/en/article/news/an-artificial-heart-valve-with-the-potential-to-grow
Article - 02/06/2017 SÜDPACK: a great example of biotech as a cross-sectoral technology SÜDPACK Verpackungen is a qualified supplier of plastic films to the biopharmaceutical industry. The company is the leading European manufacturer of packaging products for the food industry and also offers its expertise to the biopharmaceutical industry. In 2011, SÜDPACK created an exclusive cooperation partnership with Sartorius Stedim Biotech, a global technology provider for the pharmaceutical biotech industry, which has now been extended…https://www.gesundheitsindustrie-bw.de/en/article/news/suedpack-a-great-example-of-biotech-as-a-cross-sectoral-technology
Article - 24/05/2017 Ralf Reski: from moss to humans Prof. Dr. Ralf Reski conducts basic research at the University of Freiburg. But this is not all the well-known plant biotechnologist does. He also wants his ideas to become concrete products. This is why he established Greenovation Biotech GmbH, a company which produces novel drugs in mosses. The company’s first moss-produced drug candidate – Moss-aGal – a recombinant form of human α-galactosidase, is now being tested in a phase I clinical trial.…https://www.gesundheitsindustrie-bw.de/en/article/news/ralf-reski-from-moss-to-humans
Press release - 04/11/2016 Rentschler expands cGMP manufacturing capacity following increased international demand https://www.gesundheitsindustrie-bw.de/en/article/press-release/rentschler-erweitert-cgmp-produktionskapazitat-wegen-steigender-internationaler-nachfrage
Company profile - 25/07/2016 300MICRONS: 3D cell culture solutions tailored to customer needs What happens in tissues and organs and how do they react to pharmaceutical substances? Three-dimensional cell cultures can reproduce reality far better than a single-cell layer can. With good reason. Reality is far from two-dimensional. A company called 300MICRONS GmbH develops films with tiny indentations that provide optimal conditions for cells to grow into 3D cell aggregates.https://www.gesundheitsindustrie-bw.de/en/article/news/300microns-3d-cell-culture-solutions-tailored-to-customer-needs
Article - 16/06/2016 Microfluidic biofermenter mimics plant tissue It is estimated that as many as one million secondary plant metabolites can be used as medical agents. Plants produce these compounds to aid their growth and development as well as to discourage herbivores from eating them. However, it is still very difficult, or even impossible, to produce secondary plant metabolites industrially. Researchers from the Karlsruhe Institute of Technology (KIT) are now developing a microfluidic bioreactor to make…https://www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-biofermenter-mimics-plant-tissue
Retrospective Meet & Match Pharmaceutical Process Technology - 07/04/2016 Speed dating for Pharmaceutical Process Technology – a business flirt at Bosch The speed dating format is no longer just a popular and simple dating method for lonely hearts, but has also become a rewarding way for establishing new business contacts and connections quickly and efficiently. BIOPRO Baden-Württemberg chose speed networking, as speed dating is called in the corporate world, for its recent Meet & Match event on pharmaceutical process technology, which took place on 15th March 2016 with the support of Bosch…https://www.gesundheitsindustrie-bw.de/en/article/press-release/speed-dating-for-pharmaceutical-process-technology-a-business-flirt-at-bosch
Pharmaceutical research and life sciences profit from unique biosensor technology - 18/09/2015 Biametrics GmbH concludes financing round with 3.1 Million Euro Biametrics GmbH today announced the completion of their most recent financing round with €3.1 Million. Partners of the A Series Investment were LBBW Venture GmbH, MBG Mittelständische Beteiligungsgesellschaft BW, and KfW Bankengruppe. Together with seed investors HTGF and Seedfonds BW, they are aiming to accelerate the expansion of Biametrics’ bioanalytical business activities to an international level. The fresh capital will facilitate the…https://www.gesundheitsindustrie-bw.de/en/article/press-release/biametrics-gmbh-concludes-financing-round-with-31-million-euro
Article - 14/09/2015 A membrane for protein factories of the future The cellular protein machinery is a marvel of nature and produces umpteen different proteins. Most of these proteins pass through a stack of membrane-enclosed discs, known as the Golgi apparatus, a miniature reaction chamber where the finishing touch is progressively added to the proteins. Rudolf Hausmann, professor and head of the Department of Bioprocess Engineering at the University of Hohenheim, is developing membranes based on the Golgi…https://www.gesundheitsindustrie-bw.de/en/article/news/a-membrane-for-protein-factories-of-the-future
Article - 02/02/2015 Rentschler Biotechnologie invests in new production plant The Laupheim-based contract manufacturer Rentschler Biotechnologie GmbH is greatly expanding its production capacities. The company is investing €24 million in the construction of two 3,000 litre stainless steel bioreactors, which should be operational in early 2017 and will more than double the production capacities for cell culture-derived proteins. Rentschler also announced recently that it was adding a new 2,000 litre single-use bioreactor…https://www.gesundheitsindustrie-bw.de/en/article/news/rentschler-biotechnologie-invests-in-new-production-plant
Article - 10/06/2014 Mathematical models for predicting cellular signalling pathways The micrometre-sized cells in organisms are biological systems in which countless vital processes take place. However little is yet known about most of these cellular metabolic chains because they interact with each other in a complicated manner. The research carried out by junior professor Nicole Radde and her doctoral student and engineer Patrick Weber from the Institute for Systems Theory and Automated Control IST at the University of…https://www.gesundheitsindustrie-bw.de/en/article/news/mathematical-models-for-predicting-cellular-signalling-pathways
Guest article - 15/04/2013 Varied and multi-facetted – life and research in Nanjing Joachim Koepff spent six months in Nanjing from June to November 2012 doing practical training at the College for Biotechnology and Pharmaceutical Engineering. Here he recounts his experiences in China and his thoughts about the Baden-Württemberg Ministry of Science Research and the Arts scholarship that makes such short-term research stays at a Chinese research institution possible.https://www.gesundheitsindustrie-bw.de/en/article/news/varied-and-multi-facetted-life-and-research-in-nanjing
Article - 17/12/2012 Medicyte GmbH – gold standard for human cells Medicyte GmbH is a life sciences company located in the city of Heidelberg. It focuses primarily on the production of quasi-primary human cells of the highest quality and in virtually unlimited quantity. MediCyte’s goal is to establish its proprietary cell proliferation technologies as gold standard for the use of human cells and cell products in research, development and cell therapy.https://www.gesundheitsindustrie-bw.de/en/article/news/medicyte-gmbh-gold-standard-for-human-cells
Article - 15/10/2012 Rudolf Hausmann – green surfactants from bacteria In April 2012 Rudolf Hausmann jr. was appointed professor of the newly established chair of bioprocess engineering at the University of Hohenheim. His passion biosurfactants used in cleaning agents detergents and foods which will in the future enable normally non-mixable liquids such as oil and water to be mixed together.https://www.gesundheitsindustrie-bw.de/en/article/news/rudolf-hausmann-green-surfactants-from-bacteria
Dossier - 08/10/2012 Marine biotechnology: unknown sources of hope from the depths of the sea Biotechnological methods are used to investigate marine life and the results obtained from these investigations advance research in the fields of medicine and energy and into substances used as food supplements and cosmetics. The area of marine biotechnology is fairly diverse. Although it is not on the coast even the southern German state of Baden-Württemberg is involved in marine biotechnology.https://www.gesundheitsindustrie-bw.de/en/article/dossier/marine-biotechnology-unknown-sources-of-hope-from-the-depths-of-the-sea
Article - 23/07/2012 Inhospitable niches are a rich source of extremozymes At first sight nothing much seems to grow in either the Namib desert or the Antarctic. However a closer inspection of the ground a few centimetres below the surface reveals an enormous diversity of organisms. Industry is well aware of this rich source of microorganisms that have something to offer on the molecular level as well as for use in technical applications. So-called extremozymes have long been popular ingredients in cosmetics detergents…https://www.gesundheitsindustrie-bw.de/en/article/news/inhospitable-niches-are-a-rich-source-of-extremozymes
Press release - 19/07/2012 Subitec GmbH raises 4.5 Mio Euros in second round financing Subitec GmbH, a manufacturer of fully automated algae photobioreactors, hascloseda second round of financing. The CleantechFonds of eCAPITAL entrepreneurial Partners AG, Fraunhofer Venture, High-Tech Gründerfonds (HTGF) and KfW Bankengruppe’s ERP-Startfonds participated in the capital increase. Subitec funds to the amount of 4.5 Mio Euros will accrue in this round of financing. The raised capital is to be used mainly for launching bioreactors on…https://www.gesundheitsindustrie-bw.de/en/article/press-release/subitec-gmbh-raises-4-5-mio-euros-in-second-round-financing
Article - 16/07/2012 Laupheim to become an international forum for biomanufacturing The 2nd Laupheimer Zelltage conference organized by Rentschler Biotechnologie GmbH in Laupheim on 11th and 12th June 2012 focused on “Bioprocess light”. Twelve experts from applied research institutions and biotech companies from Germany and abroad provided the 200 or so guests with information on how modern bioproduction methods can be made simpler, more robust, cheaper, more reliable and hence more competitive.https://www.gesundheitsindustrie-bw.de/en/article/news/laupheim-to-become-an-international-forum-for-biomanufacturing
Press release - 05/06/2012 Engineered moss produces human hormone Erythropoietin (EPO) is a human protein hormone that is predominantly produced in kidneys. Scientists from the Chair of Plant Biotechnology of the University of Freiburg, Germany, around Dr. Eva Decker and Professor Ralf Reski and from the Freiburg-based biotech company greenovation have genetically engineered the moss Physcomitrella patens in such a way that it now produces recombinant human asialo-EPO in the moss bioreactor. The researchers…https://www.gesundheitsindustrie-bw.de/en/article/press-release/engineered-moss-produces-human-hormone
Article - 19/03/2012 Goal: online glucose sensor for bioreactors Microorganisms and sensitive cells that are grown in bioreactors need a well-regulated environment and a food supply in order to do what they are supposed to do: grow and produce biomass and metabolites. Many fermenters are equipped with sensors that continuously measure critical bioprocess parameters, including temperature, pH value and oxygen. Online glucose and ethanol sensors are not yet used in regulated bioreactors, even though they would…https://www.gesundheitsindustrie-bw.de/en/article/news/goal-online-glucose-sensor-for-bioreactors
Dossier - 12/03/2012 Regenerative medicine makes use of patients’ own resources Regenerative medicine offers new therapeutic options for many diseases in which organ function or structure are damaged or lost. The majority of regenerative therapies involve cell-based methods that are often combined with innovative biomaterials. Regenerative therapies combine know-how from the biosciences with state-of-the-art medical technology and also benefit from progress in the engineering and material sciences.https://www.gesundheitsindustrie-bw.de/en/article/dossier/regenerative-medicine-makes-use-of-patients-own-resources
Press release - 26/09/2011 Unraveling the properties of plant substances Researchers from the Institute of Analytical Chemistry at the Mannheim University of Applied Sciences are focusing on sensors in their effort to increase the yields of bioreactors and reduce the number of animals used for toxicity testing of pharmaceuticals. In addition, the chemists from Mannheim are aiming to investigate the activity of plant substances in the Bioactive Plant Foods Network, a transnational network for the promotion of bioactive…https://www.gesundheitsindustrie-bw.de/en/article/press-release/unraveling-the-properties-of-plant-substances
Article - 01/09/2011 Quality by Design – a paradigm change in bioprocess development Bioprocess technology has undergone a fundamental change with regard to the criteria used for validating product quality: around ten years ago, the U.S. Food and Drug Administration (FDA) revised the 1987 process validation guidance and the subsequent establishment of the Process Analytical Technology (PAT) initiative heralded a paradigm change in bioprocess understanding and control. The FDA’s guidance underwent a paradigm shift from what was…https://www.gesundheitsindustrie-bw.de/en/article/news/quality-by-design-a-paradigm-change-in-bioprocess-development
Article - 25/07/2011 Cell culturing as a taught subject: many more “Biberachs” are needed Cell culture technology is only taught at a handful of universities. However, this interdisciplinary subject is the core of the “Pharmaceutical Biotechnology” programme offered by the Biberach University of Applied Sciences. We talked about the subject with Professor Jürgen Hannemann, founding dean of the “Pharmaceutical Biotechnology” programme, and with Professor Friedemann Hesse, who runs the “cell culture technology” teaching programme.https://www.gesundheitsindustrie-bw.de/en/article/news/cell-culturing-as-a-taught-subject-many-more-biberachs-are-needed
Article - 25/07/2011 Cell culture technology: hamster cells and the production of biopharmaceuticals Biopharmaceuticals are one of the best selling drugs. The majority of successful biopharmaceutical ingredients are produced in CHO cell lines. Strong competition forces biopharmaceutical producers to continuously improve the drug development process and the production methods, which requires highly qualified experts.https://www.gesundheitsindustrie-bw.de/en/article/news/cell-culture-technology-hamster-cells-and-the-production-of-biopharmaceuticals